Project Grant R43AI102292

Federal Project Grant Award Summary Mapp Biopharmaceutical, Inc. received a $993,353 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 24, 2025, with performance through August 31, 2028. The grant funds development of MBP002, a fully human monoclonal antibody (mAb) product designed for respiratory syncytial virus (RSV) immunoprophylaxis in neonates and infants. MBP002 is...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $802,421 to the University of Pittsburgh on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a prospective cohort study evaluating the long-term immunogenicity and protective efficacy of the RSVPreF vaccine in pregnant women and their infants. The project will deliver scientific findings on the durability of maternal RSV (Respiratory...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vanderbilt University Medical Center a $3.3 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 11, 2025, to examine the real-world effectiveness and uptake of newly approved Respiratory Syncytial Virus (RSV) maternal vaccines and monoclonal antibodies. The research will assess comparative effectiveness, cost-effectiveness, safety, and...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $364,484 through the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, to support research on soluble guanylate cyclase (SGC) pathway activation as a novel bronchodilation strategy for respiratory syncytial virus (RSV) bronchiolitis in pediatric populations. The research project, with an ultimate completion date of June 30, 2027,...

Federal Grant Award Summary Oklahoma State University received a $403,320 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 16, 2026, with completion targeted for January 31, 2028. The award funds research and development of a novel live-attenuated respiratory syncytial virus (RSV) vaccine designed for neonatal infants under 28 days of age. The project focuses on...

Federal Project Grant Award Summary Award Details: The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.86 million Project Grant to Massachusetts General Hospital (MGH) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, with a completion date of January 31, 2030. The MARVELOUS study (Maternal RSV Vaccination—Evaluating Optimal Immune Responses) investigates immune responses in pregnant women receiving respiratory syncytial...

Federal Project Grant Award Summary Inhalon Biopharma, Inc. received a $1,013,468 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 1, 2025, with completion targeted for July 31, 2028. The company is developing IN-003PI, a passive immunization therapeutic comprised of a pair of neutralizing monoclonal antibodies (mAbs) against human metapneumovirus (MPV) fusion proteins....

L2 Diagnostics LLC received a $299,954 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 15, 2025, with an ultimate completion date of August 31, 2027. This Phase I feasibility Small Business Technology Transfer (STTR) project focuses on the development and optimization of PFAG, a novel multivalent peptide vaccine against malaria composed of synthetic peptides...

Grant Award Summary Children's Mercy Hospital received a $433,175 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. The award supports the development of a mosaic messenger ribonucleic acid (mRNA) vaccine designed to prevent hand, foot, and mouth disease (HFMD) caused by human enterovirus A viruses. The research deliverables include the design...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University $775,187 on August 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a five-year research project examining the impact of systemic immunosuppression on respiratory syncytial virus (RSV) antibody generation and effector functions following vaccination. The research will systematically study antibody responses to novel...